Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04666688 · ClinicalTrials.gov registry record · Phase 1
LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors
A Phase 1 study of Colorectal Cancer and Pancreatic Cancer, sponsored by PureTech.
- Completed
- Registry status
- Phase 1
- Development phase
- 44
- Enrollment target
- 12
- Study locations
NCT04666688: Completed Phase 1 study of Colorectal Cancer and Pancreatic Cancer, sponsored by PureTech.
NCT04666688 is a Phase 1 study of Colorectal Cancer and Pancreatic Cancer that has completed, run by PureTech. The registered enrollment target is 44 participants, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower). The trial reports 12 study locations across 8 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04666688, a Phase 1 study of Colorectal Cancer and Pancreatic Cancer, has completed, sponsored by PureTech.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 44 participants
- Enrollment target
- 12
- Study locations
Study Summary
A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
Primary Outcome
Evaluation of safety parameters including treatment emergent adverse events as detected by hematology, chemistry, coagulation safety labs, physical exams, vital signs, ECG, ECHO/MUGA, ECOG status.
Conditions Studied
Interventions
- DRUG Tislelizumab
- DRUG LYT-200
- DRUG Gemcitabine/nab-paclitaxel
Study Locations (12)
Colorado
- University of Colorado Hospital - Denver
- Sarah Cannon Research Institute at Health One - Denver
Massachusetts
- Massachusetts General Hospital - Boston
- Beth Israel Deaconess Medical Center - Boston
New York
- Columbia University - New York
- Memorial Sloan-Kettering Cancer Center - New York
Texas
- University of Texas, M.D. Anderson Cancer Center - Houston
- South Texas Accelerated Research Therapeutics - San Antonio
California
- UCLA - Los Angeles
Florida
- Sarah Cannon Research Institute, Florida Cancer Specialists - Sarasota
Michigan
- South Texas Accelerated Research Therapeutics - Grand Rapids
Tennessee
- Sarah Cannon Research Institute, Tennessee Oncology - Nashville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 44 participants |
| Start Date | 2020-12-15 |
| Est. Completion | 2024-12-12 |
| Phase | Phase 1 |
What the finished NCT04666688 record still lists
NCT04666688 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 44 participants, a relatively small participant target, below the 1,545-participant average among 381 other Colorectal Cancer trials with a reported enrollment target (97% lower).
The record links to 6 conditions, with Colorectal Cancer appearing as the primary indexed condition, and to 3 interventions - of which Tislelizumab is the first listed.
NCT04666688 lists 12 locations in 8 states (Colorado, Massachusetts, New York).
Frequently Asked Questions
What is clinical trial NCT04666688 about?
NCT04666688 is a clinical study titled "LYT-200 Alone and in Combination With Chemotherapy or Tislelizumab in Patients With Locally Advanced or Metastatic Solid Tumors". A Phase 1/2 Open-label, Multi-center Study of the Safety, Pharmacokinetics, and Anti-tumor Activity of LYT-200 Alone and in Combination with Chemotherapy or Tislelizumab in Patients with Metastatic Solid Tumors
What is the current status of trial NCT04666688?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 44 participants. The study started on 2020-12-15. Estimated completion is 2024-12-12.
What conditions does trial NCT04666688 study?
This clinical trial studies the following conditions: Colorectal Cancer, Pancreatic Cancer, Head and Neck Cancer, Solid Tumor, Metastatic Cancer.
What interventions are being tested in trial NCT04666688?
The interventions under investigation include: Tislelizumab (DRUG), LYT-200 (DRUG), Gemcitabine/nab-paclitaxel (DRUG).
Who is sponsoring clinical trial NCT04666688?
This trial is sponsored by PureTech, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04666688 being conducted?
This trial has 12 study locations across California, Colorado, Florida, Massachusetts, Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Colorectal Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04666688's enrollment target sits among peer trials
44 287th of 381 higher than 92 of 381 other Colorectal Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Colorectal Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Phase 1 Trial of ZM008 as Single Agent and in Combination With Pembrolizumab in Patients With Advanced Solid Tumors
RECRUITING · Phase 1
-
[18F]FPyQCP PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications
RECRUITING · Phase 1
-
Beamion BCGC-1: A Study to Find a Suitable Dose of Zongertinib Used Alone and in Combination With Other Treatments to Test Whether it Helps People With Different Types of HER2+ Cancer That Has Spread
RECRUITING · Phase 1
-
Study of CRX100 as Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Solid Malignancies
RECRUITING · Phase 1
-
A Study to Investigate ALE.P03 as Monotherapy in Adult Patients With Selected Advanced or Metastatic CLDN1+ Solid Tumors
RECRUITING · Phase 1
-
Phase I Study of [177Lu]Lu-NNS309 in Patients With Pancreatic, Lung, Breast and Colorectal Cancers
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02323945 · 44 participants · NA
Effects of Breathing Mild Bouts of Low Oxygen on Limb Mobility After Spinal Injury
- NCT03093909 · 44 participants · Phase 1
Study of Aerosol Gemcitabine in Patients With Solid Tumors and Pulmonary Metastases
- NCT03104491 · 44 participants · Phase 1
Inotuzumab Ozogamicin Post-Transplant For Acute Lymphocytic Leukemia
- NCT03781765 · 44 participants · Phase 4
Stimulant vs. Non-stimulant Treatments and Reward Processing in Drug-naive Youth at SUD Risk
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI